CARVYKTI

This brand name is authorized in United States. It is also authorized in Canada, Croatia, Estonia, France, Lithuania, Romania.

Active ingredients

The drug CARVYKTI contains one active pharmaceutical ingredient (API):

1	Ciltacabtagene autoleucel UNII 0L1F17908Q - CILTACABTAGENE AUTOLEUCEL
	Ciltacabtagene autoleucel is a BCMA-directed, genetically modified autologous T cell immunotherapy, which involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells.
	Read more about Ciltacabtagene autoleucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CARVYKTI Dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01X	Other antineoplastic agents	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents
Discover more medicines within L01X

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02535270
EE	Ravimiamet	1885057, 1885068
FR	Base de données publique des médicaments	64743778
LT	Valstybinė vaistų kontrolės tarnyba	1094945
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68977001
US	FDA, National Drug Code	57894-111